These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22030265)

  • 21. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.
    Onuma Y; Serruys PW; Perkins LE; Okamura T; Gonzalo N; García-García HM; Regar E; Kamberi M; Powers JC; Rapoza R; van Beusekom H; van der Giessen W; Virmani R
    Circulation; 2010 Nov; 122(22):2288-300. PubMed ID: 20975003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
    Okamoto N; Ueda H; Yoshimura T; Chamaria S; Bhatheja S; Vengrenyuk Y; Rabiei S; Barrientos Y; Kapur V; Barman N; Sweeny J; Baber U; Mehran R; Sharma SK; Kini AS
    J Invasive Cardiol; 2018 Jul; 30(7):251-255. PubMed ID: 29656280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is high pressure postdilation safe in bioresorbable vascular scaffolds? Optical coherence tomography observations after noncompliant balloons inflated at more than 24 atmospheres.
    Fabris E; Caiazzo G; Kilic ID; Serdoz R; Secco GG; Sinagra G; Lee R; Foin N; Di Mario C
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):839-46. PubMed ID: 26370357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impacts of lesion angle on incidence and distribution of acute vessel wall injuries and strut malapposition after drug-eluting stent implantation assessed by optical coherence tomography.
    Minami Y; Ong DS; Uemura S; Wang Z; Aguirre AD; Mukhopadhyay S; Soeda T; Vergallo R; Jia H; Tian J; Hu S; Kim SJ; Park CB; Dauerman HL; Lee S; Jang IK
    Eur Heart J Cardiovasc Imaging; 2015 Dec; 16(12):1390-8. PubMed ID: 25925215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold.
    Karanasos A; Simsek C; Gnanadesigan M; van Ditzhuijzen NS; Freire R; Dijkstra J; Tu S; Van Mieghem N; van Soest G; de Jaegere P; Serruys PW; Zijlstra F; van Geuns RJ; Regar E
    J Am Coll Cardiol; 2014 Dec; 64(22):2343-56. PubMed ID: 25465421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH).
    Simsek C; Magro M; Onuma Y; Boersma E; Smits P; Dorange C; Veldhof S; Regar E; Serruys PW; van Geuns RJ
    EuroIntervention; 2014 Jun; 10(2):236-40. PubMed ID: 23999210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment.
    Sorrentino S; De Rosa S; Ambrosio G; Mongiardo A; Spaccarotella C; Polimeni A; Sabatino J; Torella D; Caiazzo G; Indolfi C
    BMC Cardiovasc Disord; 2015 Dec; 15():169. PubMed ID: 26654975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial.
    Nakatani S; Onuma Y; Ishibashi Y; Muramatsu T; Iqbal J; Zhang YJ; van Geuns RJ; Ormiston JA; Serruys PW
    EuroIntervention; 2015 Mar; 10(11):1288-98. PubMed ID: 24572936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience.
    Karanasos A; Van Mieghem N; van Ditzhuijzen N; Felix C; Daemen J; Autar A; Onuma Y; Kurata M; Diletti R; Valgimigli M; Kauer F; van Beusekom H; de Jaegere P; Zijlstra F; van Geuns RJ; Regar E
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT).
    Kim JS; Kim BK; Jang IK; Shin DH; Ko YG; Choi D; Hong MK; Cho YK; Nam CW; Hur SH; Choi JH; Song YB; Hahn JY; Choi SH; Gwon HC; Jang Y
    Am Heart J; 2012 Apr; 163(4):601-7. PubMed ID: 22520526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.
    Gomez-Lara J; Brugaletta S; Farooq V; van Geuns RJ; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Morel MA; Dorange C; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2011 Jul; 4(7):789-99. PubMed ID: 21777888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II).
    Ishibashi Y; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Garcia-Garcia HM; Bartorelli AL; Whitbourn R; Chevalier B; Abizaid A; Ormiston JA; Rapoza RJ; Veldhof S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1715-26. PubMed ID: 26585622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions: Impact of polymeric wide struts on side-branch impairment.
    De Paolis M; Felix C; van Ditzhuijzen N; Fam JM; Karanasos A; de Boer S; van Mieghem NM; Daemen J; Costa F; Bergoli LC; Ligthart JM; Regar E; de Jaegere PP; Zijlstra F; van Geuns RJ; Diletti R
    Int J Cardiol; 2016 Oct; 221():656-64. PubMed ID: 27423087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optical coherence tomography evaluation of in-stent restenotic lesions with visible microvessels.
    Kim BK; Kim JS; Shin DH; Ko YG; Choi D; Jang Y; Hong MK
    J Invasive Cardiol; 2012 Mar; 24(3):116-20. PubMed ID: 22388303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance.
    Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C
    Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?
    Brugaletta S; Heo JH; Garcia-Garcia HM; Farooq V; van Geuns RJ; de Bruyne B; Dudek D; Smits PC; Koolen J; McClean D; Dorange C; Veldhof S; Rapoza R; Onuma Y; Bruining N; Ormiston JA; Serruys PW
    Eur Heart J; 2012 Jun; 33(11):1325-33. PubMed ID: 22507972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
    Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R
    EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation.
    Radu MD; Räber L; Heo J; Gogas BD; Jørgensen E; Kelbæk H; Muramatsu T; Farooq V; Helqvist S; Garcia-Garcia HM; Windecker S; Saunamäki K; Serruys PW
    EuroIntervention; 2014 Jan; 9(9):1085-94. PubMed ID: 24064426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Change in lumen eccentricity and asymmetry after treatment with Absorb bioresorbable vascular scaffolds in the ABSORB cohort B trial: a five-year serial optical coherence tomography imaging study.
    Suwannasom P; Sotomi Y; Asano T; Koon JN; Tateishi H; Zeng Y; Tenekecioglu E; Wykrzykowska JJ; Foin N; de Winter RJ; Ormiston JA; Serruys PW; Onuma Y
    EuroIntervention; 2017 Apr; 12(18):e2244-e2252. PubMed ID: 27993756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.